Pramiracetam
Pramistar · Remen · Neupramir · CI-879 · Diisopropyl-oxo-pyrrolidine acetamide
Last updated
At a glance
Overview
Pramiracetam is the racetam that actually feels like something. Where piracetam at 4800mg a day reads as a subtle nudge, pramiracetam at 400mg produces a noticeable sharpening of working memory, verbal fluency, and sustained attention within the first week — the payoff of a lipid-soluble molecule that crosses the blood-brain barrier efficiently and hits high-affinity choline uptake harder per milligram than anything else in the class.
The community running it splits cleanly into two camps: cognitive-load users stacking 400mg BID with alpha-GPC for deep-work blocks, exam prep, and long coding or writing sessions; and physique-focused users patching the "tren brain" and cutting-phase word-finding deficits that come with aggressive dieting or harsh AAS protocols. The clinical literature anchors both — the McLean 1991 TBI trial ran 1200mg/day for 18 months with sustained memory improvement and no notable adverse events, and the Auteri PK work showed clean tolerability through 1600mg single doses.
"No significant side effects were observed at any dose level up to 1600 mg. The elimination half-life was 4.5–6.5 hours, and the compound was well absorbed following oral administration." — Auteri et al., Clinical Pharmacology & Therapeutics (1985)
The catch is substrate: pramiracetam upregulates choline uptake, so without a choline precursor (alpha-GPC or CDP-choline) alongside each dose, the cholinergic system runs dry and produces the signature racetam headache. Get the pairing right and the compound delivers; get it wrong and users quit assuming it didn't work.
The sections below cover documented pramiracetam dosing, the choline stack, timing around the 4–6 hour half-life, racetam and modafinil combinations, side-effect management, and the common protocol mistakes that flatten the response.
How Pramiracetam works
High-Affinity Choline Uptake (HACU) — The Primary Mechanism#
Pramiracetam's defining action is the upregulation of high-affinity choline uptake into septohippocampal and cortical cholinergic terminals. HACU is the rate-limiting step for acetylcholine synthesis — more choline in the terminal means more ACh available for release during cognitive demand. Unlike donepezil or galantamine, pramiracetam does not bind cholinergic receptors and does not inhibit cholinesterase; it simply feeds the synthesis pathway more substrate, which is why the entire effect collapses without adequate dietary or supplemental choline.
"Pramiracetam increased high-affinity choline uptake in the hippocampus and cortex, stimulating acetylcholine synthesis and utilization without affecting receptor binding." — Pepeu G, Spignoli G, Progress in Neuropsychopharmacology & Biological Psychiatry, 1989
The practical consequence for the physique-and-optimization crowd: pramiracetam is a cholinergic amplifier, not a cholinergic agonist. Pair it with 300 mg alpha-GPC or 250 mg CDP-choline per dose, or expect the signature racetam headache rather than the documented recall effect.
Indirect Cholinergic Signalling (Not Receptor-Mediated)#
Schindler's work established that pramiracetam's memory-enhancing effect is not blocked by cholinergic receptor antagonists — meaning the mechanism sits upstream of the muscarinic/nicotinic synapse. It restores cholinergic throughput rather than stimulating receptors directly, which is why the subjective profile is clean (no jaw tension, no cramping, no parasympathetic overdrive) compared to direct cholinomimetics.
"The memory-enhancing activity of pramiracetam was not antagonized by cholinergic receptor blockade, suggesting its effects are mediated by choline uptake facilitation rather than direct receptor interaction." — Schindler U, Progress in Neuropsychopharmacology & Biological Psychiatry, 1989
This is the mechanistic reason pramiracetam plays well with stimulants (caffeine, modafinil) and with other racetams — there is no receptor-level competition, just a shared upstream substrate pool.
Adrenal-Dependent Peripheral–Central Loop#
Pramiracetam is unusual among the racetams in that its cognitive effect appears to require intact adrenal function. Adrenalectomized rodents lose the memory-enhancement signal entirely, and partial rescue is achievable with corticosterone or epinephrine replacement. This implicates a peripheral signalling loop — likely involving adrenal catecholamine release — that feeds back into central cholinergic tone.
"Pramiracetam demonstrates potent memory-enhancing effects that are dependent on intact adrenal function, suggesting a unique peripheral-central interaction compared to piracetam." — Malykh AG, Sadaie MR, Drugs, 2010
Practically: users with flattened adrenal output — late-stage aggressive cuts, chronic overtraining, high-dose ketoconazole or mitotane protocols — may blunt the response. For recomp-focused users running pramiracetam through a deficit, adequate sleep, salt, and avoidance of adrenal suppressants preserve the effect.
Lipophilicity, BBB Penetration, and the Potency Gap vs Piracetam#
Pramiracetam is the diisopropyl-aminoethyl analog of piracetam — structurally, the polar amide nitrogen is replaced with a lipid-soluble side chain. The result is a molecule that crosses the blood–brain barrier at a dramatically higher rate per milligram, which is why a 400 mg pramiracetam dose produces a subjective effect comparable to 2–4 g of piracetam.
The Auteri pharmacokinetic study in healthy male volunteers confirmed the clean PK profile that makes this compound practical: rapid oral absorption, linear dose-proportionality through 1600 mg, and a predictable 4.5–6.5 hour elimination half-life.
"No significant side effects were observed at any dose level up to 1600 mg. The elimination half-life was 4.5–6.5 hours, and the compound was well absorbed following oral administration." — Auteri A, Blardi P, Celasco G, Segre G, et al., Clinical Pharmacology & Therapeutics, 1985
The lipophilicity also drives the fed-state absorption advantage — administration with ~10 g of dietary fat produces noticeably cleaner onset than fasted dosing. This is the mechanistic reason the community consensus is "dose with breakfast, second dose with lunch."
Sustained Memory Consolidation (Clinical Translation)#
The cholinergic-throughput mechanism translates to durable endpoint benefit in the one major placebo-controlled human trial — the McLean TBI study, which ran 400 mg three times daily in young males with post-injury memory deficits and tracked delayed recall over an 18-month open-label extension.
"Pramiracetam produced statistically significant improvement in memory over placebo that was sustained throughout the 18 months of open-label extension." — McLean A Jr, Cardenas DD, Burgess D, Gamzu E, Brain Injury, 1991
No tolerance development was observed over 18 months — which is the mechanistic argument against aggressive cycling. The 4–8 week on / 1–2 week off pattern favoured in community protocols is convention rather than evidence-based necessity, though it remains a reasonable default for users who want to verify baseline cognition periodically.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 300–600 mg | Twice daily | Documented entry-level range |
| Mid | 600–800 mg | Twice daily | Most commonly studied range |
| High | 800–1200 mg | Twice daily | Split AM and early afternoon. Second dose by 2 PM — the 4–6 hour half-life means later dosing tails into sleep onset. Administered with ~10g of dietary fat to optimize absorption of this lipophilic molecule. Clinical TBI protocol used 400mg three times daily (1200mg/day). |
Cycle length & outcomes
Documented cycle
4–8 weeks
Plateau after
8 wks
Cycle Structure#
Pramiracetam is a cognition activator, not a hormonal compound — no HPG suppression, no receptor downregulation in the classical sense, and no PCT. The cycling logic is purely subjective: most users report the "click" is sharpest in the first 4–6 weeks, then begins to feel like baseline as the cognitive lift is normalized. A 1–2 week washout restores the novelty, though the 18-month open-label extension in the McLean TBI trial documented sustained benefit without tapering.
"Pramiracetam produced statistically significant improvement in memory over placebo that was sustained throughout the 18 months of open-label extension." — McLean et al., Brain Injury (1991)
Protocol Table by Goal#
| Goal | Cycle Length | Daily Dose | Split |
|---|---|---|---|
| First exposure / assessing response | 2–3 weeks | 600 mg | 300 mg AM + 300 mg early PM |
| Deep-focus / study / work block | 4–8 weeks | 800 mg | 400 mg AM + 400 mg early PM |
| Clinical-target / post-concussive recall | 4–12 weeks | 1200 mg | 400 mg TID (AM / midday / 2 PM) |
| Racetam rotation (with oxiracetam/piracetam) | 4–6 weeks | 600–800 mg | Split BID |
| Cognitive adjunct during aggressive cut | 6–8 weeks | 800 mg | Split BID |
Every dose is co-administered with 300 mg alpha-GPC or 250 mg CDP-choline and ~10 g of dietary fat. Skipping either compromises the protocol — the fat-soluble molecule absorbs poorly on an empty stomach, and the HACU mechanism stalls without choline substrate.
Onset & Time Course#
- Day 1–3: subtle. First-dose acute effects are mild; anyone expecting a modafinil-style hit will call pramiracetam inert at this stage.
- Day 3–7: the signal emerges — verbal fluency, working-memory rotation speed, and sustained attention sharpen. This is the window where users either "get it" or conclude their choline pairing is wrong.
- Week 2–4: plateau phase, and where the protocol earns its keep. Recall depth and word-finding feel effortless.
- Week 4–8: subjective novelty fades for some users while the underlying cognitive lift persists. This is the typical exit point for a cycle.
Loading & Tapering#
No loading phase is documented or necessary — linear PK through 1600 mg single doses means there's no kinetic argument for front-loading.
"The elimination half-life was 4.5–6.5 hours, and the compound was well absorbed following oral administration." — Auteri et al., Clinical Pharmacology & Therapeutics (1985)
Tapering is likewise unnecessary. Pramiracetam does not produce physical dependence, does not downregulate cholinergic receptors (its mechanism is upstream of the receptor, at choline uptake), and has no documented rebound syndrome on discontinuation. The McLean follow-up specifically checked for decay one month post-discontinuation and found the effect intact.
Dose Timing — The 2 PM Rule#
The 4.5–6.5 hour half-life is the single most important practical constraint. A 400 mg dose at 5 PM still has meaningful Cmax tail at bedtime, and users who dose late reliably report shallow sleep and vivid dreams. The protocol cutoff is 2 PM for the final dose of the day — earlier if sleep onset is already fragile. TID protocols compress the window: 7 AM / 11 AM / 2 PM works; 9 AM / 1 PM / 5 PM does not.
Bloodwork Cadence#
No routine monitoring is indicated for cognitively healthy users on standard 600–800 mg/day protocols. For anyone running the 1200 mg/day clinical-target dose long-term (>6 months), an annual CMP to verify renal function is reasonable — 40–60% of the dose clears renally unchanged, so eGFR and serum creatinine are the metrics that matter. No lipid, hormonal, or hepatic markers are meaningfully affected by pramiracetam in the published literature.
When to Cycle Off#
Exit signals that warrant a washout rather than a dose increase:
- Subjective effect has faded and choline pairing is already optimized
- Jaw tension, flat mood, or fatigue suggesting cholinergic excess (drop choline first, then consider a break)
- Frontal headache persisting despite adequate choline — indicates the pairing ratio needs adjustment, not more pramiracetam
- End of the cognitive-load block the cycle was built around (exam finished, project shipped, cut concluded)
A 1–2 week washout is standard; the compound clears fully within 48 hours, but community practice favors the longer break to reset subjective baseline before re-initiating.
Risks & mistakes
Common (most users)#
- Choline-deficiency headache — the signature racetam effect. Dull frontal or temporal ache, mild brain fog, occasional irritability. Mitigation: pair every pramiracetam dose with 300mg alpha-GPC or 250mg CDP-choline. This is non-negotiable — pramiracetam upregulates high-affinity choline uptake and will run the cholinergic system dry without substrate support.
- Mild GI discomfort — occasional nausea when dosed fasted. Mitigation: administer with ~10g of dietary fat. Pramiracetam is lipophilic and absorption improves noticeably fed.
- Transient overstimulation — mild restlessness or "wired" feeling in the first few days of a new protocol, typically resolves as the cholinergic system re-equilibrates. Mitigation: start at 300mg BID rather than jumping to 400mg BID.
- Sleep-onset interference — only when the second dose drifts past early afternoon. The 4.5–6.5 hour half-life means a 5 PM dose still has measurable Cmax tail at bedtime. Mitigation: hard cutoff at 2 PM for the second dose.
"No significant side effects were observed at any dose level up to 1600 mg. The elimination half-life was 4.5–6.5 hours, and the compound was well absorbed following oral administration." — Auteri et al., Clinical Pharmacology & Therapeutics (1985)
Uncommon (dose-dependent or individual)#
- Cholinergic excess from over-supplemented choline — paradoxically, stacking >600mg alpha-GPC per pramiracetam dose can produce jaw tension, depressive flatness, and fatigue. Mitigation: titrate choline down, not pramiracetam up. The substrate-to-activator ratio is what matters.
- Anxiety / jitteriness at the 1200mg/day tier — more common when pramiracetam is stacked with caffeine, modafinil, or noopept. Mitigation: drop the adjunct stimulants before dropping the pramiracetam dose; add 100–200mg L-theanine per dose if caffeine is non-negotiable.
- Plateau / subjective flatness after 6–8 weeks — the mechanism response has not been shown to attenuate in the 18-month open-label TBI extension, but community reports of subjective tolerance are consistent enough to take seriously. Mitigation: 1–2 week washout, verify choline substrate, reassess.
- Cognitive flatness in adrenally-suppressed subjects — the Mondadori work flagged in the Malykh review suggests pramiracetam's memory effect is dependent on intact adrenal function. Subjects running heavy glucocorticoid suppression (exogenous steroids for autoimmune management, or adrenal fatigue states) may get a muted response.
"Pramiracetam demonstrates potent memory-enhancing effects that are dependent on intact adrenal function, suggesting a unique peripheral-central interaction compared to piracetam." — Malykh & Sadaie, Drugs (2010)
Rare but serious#
- Persistent headache unresponsive to choline loading — if a frontal or temporal headache continues past 48 hours on adequate alpha-GPC or CDP-choline, discontinue and reassess. This is not a documented toxicity signal but warrants stopping the protocol rather than escalating substrate.
- Renal accumulation in impaired clearance — 40–60% of a pramiracetam dose is excreted unchanged in urine. Subjects with reduced eGFR will accumulate. Warning signs: worsening headache, nausea, or disproportionate fatigue on a previously tolerated dose. Mitigation: CMP once yearly on any 1200mg/day long-term protocol.
- Mood destabilization — rare, but some community reports describe a depressive or anhedonic shift on extended high-dose protocols. Mechanism is unclear and likely multi-factorial (cholinergic-dopaminergic balance). Discontinue and allow 2–4 weeks for baseline to return.
"Pramiracetam produced statistically significant improvement in memory over placebo that was sustained throughout the 18 months of open-label extension." — McLean et al., Brain Injury (1991)
The McLean trial is the longest continuous exposure dataset available — 18 months of open-label 1200mg/day with no notable adverse event signal. The compound is genuinely clean at clinically validated doses.
Hard contraindications#
- Pregnancy or pregnancy potential — no controlled reproductive-toxicity data. Do not use.
- Lactation — no controlled data on lacteal transfer. Do not use.
- Severe renal impairment — 40–60% renal excretion unchanged makes accumulation predictable. Contraindicated without dose adjustment under nephrology supervision.
- Choline deficiency / refusal to stack a choline source — this is a functional contraindication. Running pramiracetam without alpha-GPC or CDP-choline is not dangerous, but it guarantees the racetam headache and defeats the purpose of the protocol.
- Late-evening administration — the half-life tail will wreck sleep architecture. Second dose by 2 PM, no exceptions.
Gender-specific considerations and PCT#
Pramiracetam is non-hormonal and does not interact with the HPG axis — no PCT is required, no post-cycle bloodwork beyond a standard CMP for renal function. The compound is bodyweight-independent, so the same dosing applies across the subject pool; no virilization concern, no androgenic signal, no estrogenic signal.
For women in the subject pool: the only gender-linked caveat is the pregnancy / lactation contraindication above, which is a hard line rather than a manageable risk. For men running pramiracetam alongside AAS cycles to manage "tren brain" or working-memory degradation, the compound does not interact pharmacokinetically with testosterone esters, 19-nors, or orals — it is additive to the stack, not competitive with it.
Bottom line: pramiracetam is one of the cleanest cognition activators in the research-chemical catalog. The side-effect profile is dominated by a single, entirely preventable issue (choline substrate), and the clinical record extends to 18 months of continuous exposure without meaningful adverse events.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.02 | ×1.00 | ×1.12 |
FAQ — Pramiracetam
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Pramiracetam - Powder, 10 grams - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Pramiracetam
Research & citations
6 studies cited on this page.
Conclusion
Pramiracetam stands out in the nootropic class for its high-affinity choline uptake mechanism and reliably perceptible focus and memory benefits at moderate doses. With limited side effects and clean pharmacokinetics, it is a go-to for users seeking sharper recall, improved sustained attention, or a stimulant-free cognitive edge.
Key takeaways:
- Standard protocol: 400 mg twice daily (AM and early afternoon), always paired with 250–300 mg alpha-GPC or CDP-choline per dose
- Oral administration with ~10 g dietary fat is strongly preferred for maximal absorption and minimal GI upset
- Cycle duration: 4–8 weeks with a 1–2 week washout, though clinical data support sustained use up to 18 months in TBI populations
- Stacking: typically combines with choline, modafinil, or other racetams for targeted cognitive performance; avoid stacking all racetams simultaneously
- Headline benefit: rapid-onset improvement in working memory, verbal fluency, and focus, especially in cognitively demanding or caloric-restricted contexts
- Side effects are rare beyond the signature racetam headache, which is prevented by adequate choline supplementation
For researchers looking to anchor a reliable cognition protocol, pramiracetam remains one of the highest-signal, best-tolerated options in the nootropic space.
"No significant side effects were observed at any dose level up to 1600 mg. The elimination half-life was 4.5–6.5 hours, and the compound was well absorbed following oral administration."
— Auteri et al., 1985 (https://pubmed.ncbi.nlm.nih.gov/4008675/)
"Pramiracetam produced statistically significant improvement in memory over placebo that was sustained throughout the 18 months of open-label extension."
— McLean et al., 1991 (https://pubmed.ncbi.nlm.nih.gov/1786500/)